Precision Medicine and Next Generation Sequencing: Practical Applications John Pfeifer, MD, PhD

Transcript Precision Medicine and Next Generation Sequencing: Practical Applications John Pfeifer, MD, PhD

Precision Medicine and Next Generation Sequencing: Practical Applications

John Pfeifer, MD, PhD Washington University School of Medicine Department of Pathology

Preliminary ADASP Program (Oct. 2007)

Association of Directors of Anatomic and Surgical Pathology Saturday, March 1, 2008 Hyatt Regency Hotel HH Agate A-C 0730- 1730, MT Denver, Colorado Proposed Speaker 0730- 0800 Continental Breakfast THREATS and OPPORTUNITIES in ACADEMIC PATHOLOGY 0800-0805 0805-0835 0835-0905 0905-0935 Residency Training Welcome and Introduction Generational expectations, X, Y, Z Medical School Curricula Changes/Deficiencies Dr Otis Dr Wick Dr De Young Gaps in Resident Training Discussion and Break Dr Talbert membership Dr Farver 1055-1125 1125-1200 1200-1330 Solutions and Uncertainties Dr Brownlee Dr Moskaluk Discussion membership LUNCH (HH Mineral B) Pathology Business Innoivations and Competition 1330-1400 Laboratory Niche and Competitive Advantages Bernie Ness 1400-1430 1430-1450 Technological Advances and Threats to Pathology 1450-1520 New Imaging Advances 1520-1550 1550-1610 1610-1630 1630-1700 1700-1715 1730-1930 Opportunities for Counter Competition Collaborative Opportunities and Solutions Competition from Molecular Pathology Discussion and Break Molecular Pathology Opportunities Discussion Business Meeting Dr Deryk Reception and Adjourn (Douglas Pavillion D) Dr Worsham Dr Myers Dr Pfeifer Dr membership Dr Otis membership

Preliminary ADASP Program (Jan. 2008)

Many of the perceived challenges mix together diagnostic, prognostic, and therapeutic implications, which fosters uncertainty and anxiety  “We have recently entered a transition period in which specific genetic knowledge is becoming critical to the delivery of effective health care for everyone.” Guttmacher AE, et al. N Engl J Med 2002;347:1512-1520  “… the impending revolution in molecular and computational biology is comparable with previous periods of sweeping change in diagnostic pathology.” Finn WG. J Mol Diagn 2007;9:431-436

Patient Care

 Growing complexity of recognized genetic aberrations characteristic of specific diseases offers opportunities to develop new clinical molecular testing paradigms  Growing complexity of molecular testing paradigms offers opportunities for defining indications for testing and test interpretation  Growing demand creates opportunities for possible new revenue streams

Research opportunities

 “Considering the fact that cell function is controlled by a complex network of functionally active signaling pathways, it is unlikely that expression analysis of a single or small number of proteins will precisely predict the clinical outcome of an individual tumor.” Dietel M, et al. Virchows Arch 2006;448:744-755

Opportunities for Education: Residents and Fellows

Community hospital pathologists were recently asked to identify the skills and knowledge they expect of a newly minted pathologist:  Since…   many groups are doing at least PCR, FISH, ISH, and cytogenetics clinicians are demanding molecular testing  Groups depend on young pathologists to…    bring these techniques with them from the university know the indications for testing interpret the results Horowitz RE. Hum Pathol 2006;37:969-973

Pathology Cytogenetics Next Gen Sequencing Biomedical Informatics Microarrays Sanger Sequencing

GPS

Comprehensive Oncology Gene Set

Comprehensive Cancer Set Requirements

• • • • • • • • Have an established role in patient care for diagnosis, prognosis, or therapy Comparable performance with FFPE and frozen samples Analysis of small biopsy & cytology specimens Detect variants with as little as 20% tumor cellularity 1000x fold sequence read depth 25-30 fold sample multiplexing to reduce cost Comprehensive informatics and interpretive reporting Currently reimbursed by Sanger methodology

Practical Applications: The first thing practicing pathologists need to know is that there is no need for anxiety

      Only about 6% of cases need molecular testing In most cases tested, morphology is required to establish the need for molecular analysis In most cases tested, morphology is required to identify tissue to be evaluated Even in cases tested, molecular analysis can not currently be employed to establish stage (depth of invasion) or is untenable as a routine method for establishing stage (status of all lymph nodes) Even in cases tested, molecular analysis can not be used to evaluate the margins of excision Need more Pathologists than are available

Published guidelines are being developed that address the required fund of knowledge

   CAP, AMP, ACMG, and so on, have committees working in the personalized medicine landscape TRIG and other non-institutional working groups are developing teaching materials The CAP checklist for NGS was released summer 2012; the ACMG guidelines for NGS were just released for comment

The American Board of Pathology has yet to provide guidance

Section III Cognitive Expertise of the ABP’s “Maintenance of Certification Booklet of Information” states that: E. The ABP recognizes the breadth of pathology practice.

1. The primary examinations (AP, CP, AP/CP) will be modular and the diplomats will be able to select modules that are as relevant as possible to individual practice settings.

2. The subspecialty MOC examinations in Hematology, Molecular Genetic Pathology, Neuropathology, and Pediatric Pathology will be modular. The remainder of the subspecialty examination will consist of 150 questions covering the general practice of the subspecialty.

3. For both primary and subspecialty exams, all modules will be graded together as one examination.

4. See “MOC Presentation” on the MOC section of the ABP Web site for a proposed list of modules. These are subject to change prior to administration of the first examination in 2014.

F. The exact nature of the modules to be provided is under development… http://www.abpath.org/MOCBofI.pdf

Clinical Samples Tissue Sample Submission Pathology Assessment Accessioning DNA Isolation DNA Sample Submission Library Preparation Library Submission Sequencing Data Submission Bioinformatic Analysis

• • •

Tier 1 Base Calling Alignment Variant Calling

• •

Tier 2 Annotation Knowledgebase

•

Tier 3 Clinical Report

Practicing pathologists who do genomic pathology need some level of technical and genetic expertise

   Familiarity with different platforms (specifically those marketed by Illumina and Life Technologies)  Differences in turn around time   Differences in error rate Differences in capacity Understanding of the differences in hybridization-based approaches versus amplification-based approaches Use of panels, versus exomes, versus genomes  Subspecialty training in molecular pathology

Practicing pathologists who do genomic pathology also need some level of bioinformatic expertise

     Implications of depth of coverage for detecting germline mutations versus acquired mutations Optimization and clinical validation of bioinformatic pipelines Differences in bioinformatic approaches for SNVs, indels, CNVs, and translocations Impact of nucleic acid quantity and quality on Bayesian metrics Different -omic techniques Wood LD, et al. Science 2007;318:1109-1113 International HapMap Consortium. Nature 2007;449:851-861 Korbel JO, et al. Science 2007;318:420-426 West RB, et al. Lab Invest 2007;87:967-970

• • • •

Detection of indels varies by software tool: FLT3 ITD detection is an example Tested a set of 24 cases with known FLT3 ITDs by WUCaMP28 Pindel correctly identified ITDs in 23/24 cases Identified all ITDs (24/24) by de-novo assembly methods (detected allele frequencies of less than 4%) No false positive results red= not detected green=detected

Reference: Spencer DH et al. J Mol Diagn 2013;15:81-93

Pathologists will need to be familiar with a range of -omics techniques

     Genomics (DNA) Transcripomics (mRNA) Interferomics (iRNA) Epigenomics Tumor cells (oncomics) versus stroma (stromics)  Proteins versus nucleic acids (eg, proteomics and metabolomics)

Practicing pathologists who do genomic pathology will need to understand their central educational role to their clinical colleagues  In a model system evaluating the use of APC testing,  Only 83% of patients had valid reasons for testing (clinical features of familial adenomatous polyposis or were at risk for the disease)   The appropriate strategy for pre symptomatic testing was used in 79%, only 19% received genetic counseling before the test, and only 17% provided written informed consent In 32% of the cases the physicians misinterpreted the test results Giardiello FM, et al. N Engl J Med 1997;336:823-7

Practicing pathologists who do genomic pathology will need to understand their central educational role extends beyond their clinical colleagues to include As a source of professional information regarding so called “recreational genomics” which may cause  Needless worry    Poor medical decisions Discrimination Potential for litigation (eg, right to know, relatedness) Kaiser J. Science 2007;318:1843

A concluding note of caution…

“… the four letters of the genetic code are H, Y, P, and E, and medical providers must realize that the molecular biology business is as adept at promoting its wares as is any other.” Jones S. http://www.milbank.org/reports/000712genetics.html

Precision Medicine and Next Generation Sequencing: Practical Applications John Pfeifer, MD, PhD

Transcript Precision Medicine and Next Generation Sequencing: Practical Applications John Pfeifer, MD, PhD